MedTrace Logo

Brodalumab (AMG 827) in Adults With Moderate to Severe Crohn's Disease

NCT01150890 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 130

Last updated 2022-01-03

Study results available
· View outcomes & findings →

Summary

The study will examine the safety and effectiveness of brodalumab for the treatment of moderate to severe Crohn's disease. Participants will randomly assigned to receive either brodalumab or placebo (a lookalike liquid that doesn't have any drug in it) and neither the doctor nor the patient will know what treatment is being given.

Conditions

Interventions

BIOLOGICAL

Brodalumab

Administered as as an intravenous (IV) infusion over at least 30 minutes.

DRUG

Placebo

Administered as as an intravenous (IV) infusion over at least 30 minutes.

Sponsors & Collaborators

Principal Investigators

  • MD · Amgen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-11-09
Primary Completion
2011-10-15
Completion
2011-10-15

Countries

  • United States
  • Australia
  • Belgium
  • Canada
  • France
  • Netherlands
  • Poland
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01150890 on ClinicalTrials.gov